⌘K
Loading ticker…
As of 2026-08-24, Cardiff Oncology, Inc. Common Stock (CRDF) has a 3-month relative strength percentile of 8 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 34. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.7%, relative volume 2.11×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CRDF is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -6.7% / -43.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
CRDF is held by 11 ETFs as of May 2026. Top owner: VTWO at 0.00% weight, $617K notional. Top 3 carry $719K.
Held by 19 ETFs · $9M across latest filings · largest weight 0.03% (IWC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.00% | $617K | — |
| VTWG | 0.00% | $54K | — |
| VTWV | 0.00% | $48K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $8K | — |
| ITWO | 0.00% | $6K | — |
| URTY | 0.00% | $4K | — |
| UWM | 0.00% | $4K | — |
| MSSM | 0.00% | $3K | — |
| AVSC | 0.00% | $1K | — |
| HDG | 0.00% | $112 | — |
Showing 10 of 11 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRDF Jan avg: -2.90% median: -0.87% win: 50% σ: 27.36% n: 4 2022-04-12 → 2026-07-31 | CRDF Feb avg: 6.46% median: 8.03% win: 75% σ: 7.34% n: 4 2022-04-12 → 2026-07-31 | CRDF Mar avg: 38.87% median: -10.56% win: 25% σ: 109.47% n: 4 2022-04-12 → 2026-07-31 | CRDF Apr avg: -11.19% median: -12.74% win: 40% σ: 18.20% n: 5 2022-04-12 → 2026-07-31 | CRDF May avg: 0.10% median: 0.75% win: 60% σ: 19.26% n: 5 2022-04-12 → 2026-07-31 | CRDF Jun avg: -3.02% median: -8.70% win: 20% σ: 38.60% n: 5 2022-04-12 → 2026-07-31 | CRDF Jul avg: -6.54% median: 0.46% win: 60% σ: 22.44% n: 5 2022-04-12 → 2026-07-31 | CRDF Aug avg: 3.25% median: 1.34% win: 50% σ: 13.86% n: 4 2022-04-12 → 2026-07-31 (current) | CRDF Sep avg: -13.38% median: -13.18% win: 25% σ: 25.53% n: 4 2022-04-12 → 2026-07-31 | CRDF Oct avg: 3.44% median: 9.96% win: 75% σ: 18.25% n: 4 2022-04-12 → 2026-07-31 | CRDF Nov avg: -1.71% median: -2.72% win: 25% σ: 12.83% n: 4 2022-04-12 → 2026-07-31 | CRDF Dec avg: 24.48% median: 21.79% win: 75% σ: 32.11% n: 4 2022-04-12 → 2026-07-31 |